For leukemia cells, FTO inhibitors can not only block the signal axis of FTO/m6A/MYC/CEBPA and inhibit the self-renewal of cancer stem cells, but also suppress the expression of immune checkpoint LILRB4 and immune evasion thus enhancing the cytotoxicity of T cells (173). This evidence concerns the gene FTO and cancer.